Chicago—New clinical recommendations from the North American Menopause Society (NAMS) show that many physicians are left with more questions than answers following the recent release of data from two large clinical trials of hormone replacement therapy (HRT).
After the publication of follow-up findings from the Heart and Estrogen/progestin Replacement Study (HERS II) and a halted arm of the Women's Health Initiative (WHI), the NAMS board faced two issues: whether to respond to the findings and, if so, how best to guide clinicians who prescribe HRT.
"Rather than come out with an acute, gut response, we decided to convene an expert panel to develop recommendations to deal with what we know and what we don't know," said NAMS Executive Director Wulf Utian, MD, PhD. Utian is the Arthur H. Bill professor emeritus of reproductive biology and obstetrics and gynecology at Case Western Reserve University School of Medicine, Cleveland.
. . . [Full Text of this Article]
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter
What's this?
